Selective inhibitors of constitutive androstane receptor
The compounds of the invention are antagonists of CAR, with specificity for CAR over other proteins including PXR. The disclosed compounds are useful in treating or controlling cell proliferative disorders, in particular oncological disorders, such as cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
1. A compound having a structure represented by a formula:
wherein n is an integer selected from 1, 2, and 3;
wherein R 1 is —NR 11a R 11b ;
wherein R 11a is hydrogen and R 11b is —C(CH 3 ) 2 (C2-C8 alkyl);
wherein R 2 is selected from hydrogen and C1-C4 alkyl;
wherein R 3 is selected from —SO 2 R 12 , —(C═O)R 13 , —(C═O)NR 14a R 14b , —(C═O)OR 15 , and Ar 2 ;
wherein R 12 , when present, is selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 22a R 22b ;
wherein each of R 22a and R 22b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 22a and R 22b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 13 , when present, is selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl;
wherein each of R 14a and R 14b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 14a and R 14b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 15 , when present, is selected from hydrogen, C1-C4 alkyl, C1-C4 monohaloalkyl, C1-C4 polyhaloalkyl, and Cy 2 , provided that R 15 is i-propyl only when n is 1, and provided that when n is 1 or 2 and each of R 11a and R 11b is ethyl then R 15 is not ethyl;
wherein Cy 2 , when present, is C3-C6 cycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C1-C4 monohaloalkyl, C1-C4 polyhaloalkyl; and
wherein Ar 2 , when present, is C2-C6 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C1-C4 monohaloalkyl, C1-C4 polyhaloalkyl, and wherein two of the substituents are optionally covalently bonded, and together with the intermediate atoms, comprise an optionally substituted 5- to 6-membered fused ring group;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein R 11a is hydrogen and R 11b is —C(CH 3 ) 2 CH 2 CH 3 .
3. The compound of claim 1 , wherein R 2 is hydrogen or C1-C4 alkyl.
4. The compound of claim 1 , wherein R 3 is selected from —SO 2 R 12 , —(C═O)R 13 , —(C═O)NR 14a R 14b , and —(C═O)OR 15 .
5. The compound of claim 1 , wherein R 3 is Ar 2 .
6. A pharmaceutical composition comprising an effective amount of a compound of claim 1 , and a pharmaceutically acceptable carrier.
7. A compound having a structure represented by a formula:
wherein n is an integer selected from 1, 2, and 3;
wherein R 1 is selected from —OR 10 , —NR 11a R 11b , and Ar 1 ;
wherein R 10 , when present, is selected from hydrogen, C1-C8 alkyl, and Cy 1 ;
wherein Cy 1 , when present, is C3-C6 cycloalkyl or C2-C5 heterocycloalkyl and substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C1-C4 monohaloalkyl, C1-C4 polyhaloalkyl;
wherein each of R 11a and R 11b , when present, is independently selected from C1-C8 alkyl; or
wherein R 11a , when present, is hydrogen and R 11b , when present, is —C(CH 3 ) 2 (C2-C8 alkyl); or
wherein each of R 11a and R 11b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 5-membered heterocycle; or
wherein each of R 11a and R 11b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 6-membered heterocycle having a structure represented by a formula:
wherein Z, when present, is selected from C, NH, and NCH 3 ;
wherein each of R 20a , R 20b , R 20c , and R 20d , when present, is independently selected from hydrogen and C1-C4 alkyl, provided that R 20a and R 20b are not simultaneously hydrogen; or
wherein each of R 20a and R 20c , when present, are hydrogen and R 20b and R 20d , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 5- to 6-membered heterocycle;
wherein each of R 21a , R 21b , R 21c , and R 21d , when present, is independently selected from hydrogen and C1-C4 alkyl, provided that R 21a and R 21b are not simultaneously hydrogen; or
wherein each of R 21a and R 21c , when present, are hydrogen and R 21b and R 21d , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 5- to 6-membered heterocycle;
wherein Ar 1 , when present, is C2-C6 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C1-C4 monohaloalkyl, C1-C4 polyhaloalkyl, and wherein two of the substituents are optionally covalently bonded, and together with the intermediate atoms, comprise an optionally substituted 5- to 6-membered fused ring group;
wherein R 2 is selected from hydrogen and C1-C4 alkyl;
wherein R 3 is Ar 2 ;
wherein Ar 2 , when present, is C2-C6 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C1-C4 monohaloalkyl, C1-C4 polyhaloalkyl, and wherein two of the substituents are optionally covalently bonded, and together with the intermediate atoms, comprise an optionally substituted 5- to 6-membered fused ring group;
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 7 , wherein R 2 is hydrogen or C1-C4 alkyl.
9. The compound of claim 7 , wherein Ar 2 is C2-C6 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl.
10. The compound of claim 7 , wherein Ar 2 is C2-C6 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl, and wherein two of the substituents are covalently bonded, and together with the intermediate atoms, comprise an optionally substituted 5- to 6-membered fused ring group.
11. The compound of claim 7 , wherein Ar 2 is selected from furyl, imidazolyl, pyrimidinyl, tetrazolyl, thienyl, pyridinyl, pyrrolyl, N-methylpyrrolyl, quinolinyl, isoquinolinyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridazinyl, pyrazinyl, benzofuranyl, benzodioxolyl, benzothiophenyl, indolyl, indazolyl, benzimidazolyl, imidazopyridinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyridinyl, pyrimidinyl, thiophenyl, benzo [d] oxazolyl, benzo [d] thiazolyl, quinazolinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazolyl, and pyrido[2,3-b]pyrazinyl and substituted with 0, 1, 2, or 3 substituents independently selected from —F, —Cl, methyl, ethyl, propyl, isopropyl, tert-butyl, sec-butyl, isobutyl, tent-butyl, —OCH 3 , —OCH 2 CH 3 , —O(CH 2 ) 2 CH 3 , —OCH(CH 3 ) 2 , —CH 2 F, —CH 2 Cl, —CH 2 Br, —CH 2 I, —CH 2 CH 2 F, —CH 2 CH 2 Cl, —CH 2 CH 2 Br, —CH 2 CH 2 I, —(CH 2 ) 2 CH 2 F, —(CH 2 ) 2 CH 2 Cl, —(CH 2 ) 2 CH 2 Br, —(CH 2 ) 2 CH 2 I, —CHF 2 , —CF 3 , —CHCl 2 , —CCl 3 , —CHBr 2 , —CBr 3 , —CHI 2 , —CI 3 , —CH 2 CHF 2 , —CH 2 CF 3 , —CH 2 CHCl 2 , —CH 2 CCl 3 , —CH 2 CHBr 2 , —CH 2 CBr 3 , —CH 2 CHI 2 , —CH 2 CI 3 , —(CH 2 ) 2 CHF 2 , —(CH 2 ) 2 CF 3 , —(CH 2 ) 2 CHCl 2 , —(CH 2 ) 2 CCl 3 , —(CH 2 ) 2 CHBr 2 , —(CH 2 ) 2 CBr 3 , —(CH 2 ) 2 CHI 2 , and —(CH 2 ) 2 CI 3 .
12. The compound of claim 7 , wherein Ar 2 is selected imidazolyl, pyrimidinyl, tetrazolyl, pyridinyl, pyrrolyl, N-methylpyrrolyl, quinolinyl, isoquinolinyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridazinyl, pyrazinyl, indolyl, indazolyl, benzimidazolyl, imidazopyridinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyridinyl, pyrimidinyl, benzo [d] oxazolyl, benzo [d] thiazolyl, quinazolinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazolyl, and pyrido[2,3-b]pyrazinyl and substituted with 0, 1, 2, or 3 substituents independently selected from —F, —Cl, methyl, ethyl, propyl, isopropyl, tent-butyl, sec-butyl, isobutyl, tent-butyl, —OCH 3 , —OCH 2 CH 3 , —O(CH 2 ) 2 CH 3 , —OCH(CH 3 ) 2 , —CH 2 F, —CH 2 Cl, —CH 2 Br, —CH 2 I, —CH 2 CH 2 F, —CH 2 CH 2 Cl, —CH 2 CH 2 Br, —CH 2 CH 2 I, —(CH 2 ) 2 CH 2 F, —(CH 2 ) 2 CH 2 Cl, —(CH 2 ) 2 CH 2 Br, —(CH 2 ) 2 CH 2 I, —CHF 2 , —CF 3 , —CHCl 2 , —CCl 3 , —CHBr 2 , —CBr 3 , —CHI 2 , —CI 3 , —CH 2 CHF 2 , —CH 2 CF 3 , —CH 2 CHCl 2 , —CH 2 CCl 3 , —CH 2 CHBr 2 , —CH 2 CBr 3 , —CH 2 CHI 2 , —CH 2 CI 3 , —(CH 2 ) 2 CHF 2 , —(CH 2 ) 2 CF 3 , —(CH 2 ) 2 CHCl 2 , —(CH 2 ) 2 CCl 3 , —(CH 2 ) 2 CHBr 2 , —(CH 2 ) 2 CBr 3 , —(CH 2 ) 2 CHI 2 , and —(CH 2 ) 2 CI 3 .
13. A pharmaceutical composition comprising an effective amount of a compound of claim 7 and a pharmaceutically acceptable carrier.
14. A compound having a structure represented by a formula:
wherein n is an integer selected from 1, 2, and 3;
wherein R 1 is selected from —OR 10 , —NR 11a R 11b , and Ar 1 ;
wherein R 10 , when present, is selected from hydrogen, C1-C8 alkyl, and Cy 1 ;
wherein Cy 1 , when present, is C3-C6 cycloalkyl or C2-C5 heterocycloalkyl and substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C1-C4 monohaloalkyl, C1-C4 polyhaloalkyl;
wherein R 11a and R 11b , when present, are covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 5-membered heterocycle; or
wherein R 11a and R 11b , when present, are covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 6-membered heterocycle having a structure represented by a formula:
wherein Z, when present, is selected from C, NH, and NCH 3 ;
wherein each of R 20a , R 20b , R 20c , and R 20d , when present, is independently selected from hydrogen and C1-C4 alkyl, provided that R 20a and R 20b are not simultaneously hydrogen; or
wherein each of R 20a and R 20c , when present, are hydrogen and R 20b and R 20d , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 5- to 6-membered heterocycle;
wherein each of R 21a , R 21b , R 21c , and R 21d , when present, is independently selected from hydrogen and C1-C4 alkyl, provided that R 21a and R 21b are not simultaneously hydrogen; or
wherein each of R 21a and R 21c , when present, are hydrogen and R 21b and R 21d , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 5- to 6-membered heterocycle;
wherein Ar 1 , when present, is C2-C6 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C1-C4 monohaloalkyl, C1-C4 polyhaloalkyl, and wherein two of the substituents are optionally covalently bonded, and together with the intermediate atoms, comprise an optionally substituted 5- to 6-membered fused ring group;
wherein R 2 is selected from hydrogen and C1-C4 alkyl;
wherein R 3 is selected from —SO 2 R 12 , —(C═O)R 13 , —(C═O)NR 14a R 14b , —(C═O)OR 15 , and Ar 2 ;
wherein R 12 , when present, is selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 22a R 22b ;
wherein each of R 22a and R 22b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 22a and R 22b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 13 , when present, is selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl;
wherein each of R 14a and R 14b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 14a and R 14b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 15 , when present, is selected from hydrogen, C1-C4 alkyl, C1-C4 monohaloalkyl, C1-C4 polyhaloalkyl, and Cy 2 , provided that R 15 is i-propyl only when n is 1, and provided that when n is 1 or 2 and each of R 11a and R 11b is ethyl then R 15 is not ethyl;
wherein Cy 2 , when present, is C3-C6 cycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C1-C4 monohaloalkyl, C1-C4 polyhaloalkyl; and
wherein Ar 2 , when present, is C2-C6 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C1-C4 monohaloalkyl, C1-C4 polyhaloalkyl, and wherein two of the substituents are optionally covalently bonded, and together with the intermediate atoms, comprise an optionally substituted 5- to 6-membered fused ring group;
or a pharmaceutically acceptable salt thereof.
15. The compound of claim 14 , wherein R 1 is selected from —OR 10 and Ar 1 .
16. The compound of claim 14 , wherein R 2 is hydrogen or C1-C4 alkyl.
17. The compound of claim 14 , wherein R 3 is selected from —SO 2 R 12 , —(C═O)R 13 , —(C═O)NR 14a R 14b , and —(C═O)OR 15 .
18. The compound of claim 14 , wherein R 1 is —OR 10 , wherein the compound has a structure selected from:
19. The compound of claim 14 , wherein R 1 is Ar 1 , wherein the compound has a structure selected from:
20. A pharmaceutical composition comprising an effective amount of a compound of claim 14 and a pharmaceutically acceptable carrier.